IngredientesSyringic acid is a naturally occurring phenolic acid, classified as a methoxy derivative of hydroxybenzoic acid, characterized by a benzene ring substituted with a carboxylic acid group at position 1, a hydroxyl group at position 4, and methoxy groups at positions 3 and 5. Its systematic IUPAC name is 4-hydroxy-3,5-dimethoxybenzoic acid; it is also known as 3,5-dimethoxy-4-hydroxybenzoic acid and, in older nomenclature, as the 3,5-dimethyl ether of gallic acid. Syringic acid is a naturally occurring O-methylated phenolic acid. Its CAS Registry Number is 530-57-4.
With the molecular formula C₉H₁₀O₅ and a molar mass of 198.17 g/mol, it appears as an off-white powder that is soluble in ethanol, methanol, and ethyl ether, but only slightly soluble in water (approximately 5780 mg/L at 25°C), and has a melting point of 205–209°C.
The chemical structure of syringic acid consists of a benzene ring with a hydroxyl (–OH) group and two methoxy (–OCH₃) groups attached to the ring. The methoxy groups' presence on the aromatic ring at positions 3 and 5 is responsible for conferring the therapeutic properties of syringic acid. It is a derivative of gallic acid.
The compound takes its name from the genus Syringa, the lilacs. Syringic acid is a natural plant metabolite that is found in species such as the common lilac (Syringa vulgaris), for which it is named, and in the evergreen tree Ardisia elliptica and the flowering plant Schumannianthus dichotomus, both of which grow in southeast Asia.
Syringic acid appeared in the literature in 1911, when F. Mauthner at the Technical University of Berlin used its methyl ester to synthesize methyl pentamethyldigaliate. Three years later, German chemist Richard Lepsius prepared some of its derivatives, including 4-O-carbomethoxysyringic acid and 4-O-carbethoxysyringic acid, directly from syringic acid. In 1919, Marston Taylor Bogert and Jacob Ehrlich at Columbia University reported the synthesis of syringic acid via the sulfuric acid hydrolysis of trimethylgallic acid. The focus of their research was the use of syringic acid to produce 3,5-dimethoxyphenetidine, a compound under study at Columbia medical school as an antipyretic (fever reducer).
Chemically, syringic acid can be prepared by selectively hydrolyzing (demethylating) eudesmic acid with 20% sulfuric acid.
Syringic acid is widely distributed in various plants, fruits, vegetables, and even some fungi, serving as a key metabolite in lignification processes and contributing to the structural integrity of plant cell walls. Notable sources include olives, dates, grapes, red wine, honey, Swiss chard, walnuts, pumpkin, and the medicinal mushroom Inonotus obliquus. Syringic acid can be found in several consumables including olives, dates, spices, pumpkin, grapes, acai palm, honey, red wine, among others. It is also found in sage, wheat, açaí palm, Ardisia elliptica, and grapes.
An archaeochemically significant observation concerns the ancient Egyptian drink shedeh: its presence in the ancient Egyptian drink shedeh could confirm it was made out of grape, as syringic acid is released by the breakdown of the compound malvidin, also found in red wine. It is also found in vinegar.
Syringic acid is found in a wide variety of plants, including olives, grapes, pomegranates, mushrooms, and green tea, and acts as a plant metabolite. It is abundantly found in vegetables and fruits like black soybeans, grapes, acai palms, pumpkin, and olives.
Syringic acid is a phenolic compound synthesized via the shikimic acid pathway in plants. Syringic acid, vanillic acid, and 4-hydroxybenzoic acids are derivatives of benzoic acid, which are generally derived from corresponding cinnamic acid derivatives through the enzymatic reactions of β-oxidation. The monolignol sinapyl alcohol is the precursor for syringyl lignin (an immediate source of syringic acid), which is the major component of plant secondary cell walls.
Syringic acid is a key intermediate in the bacterial catabolism of syringyl lignin-derived aromatic compounds. In the broader context of lignin chemistry, lignin is formed by the oxidative coupling of three monomers: coniferyl alcohol (guaiacyl [G] type), sinapyl alcohol (syringyl [S] type), and p-coumaryl alcohol (p-hydroxyphenyl [H] type). Lignin monomer composition differs depending on the plant species; softwood lignins mainly consist of G-type units, whereas hardwood lignins are mainly composed of S-type and G-type units.
At the microbial level, Sphingomonas paucimobilis SYK-6 can use lignin as a carbon source through the conversion of lignin into valuable intermediate compounds. The lignin intermediates of microbial enzymatic reactions are vanillate and syringates, which are converted to protocatechuate (PCA) and 3-O-methylgallate (3MGA), respectively, by tetrahydrofolate (H4folate)-dependent O-demethylases.
Syringic acid as an isolated compound has no ancient history of use in its pure form; it has only been chemically characterized in the twentieth century. However, the plant sources richest in syringic acid have long histories in traditional medicine across multiple cultures. Syringic acid is a significant active phenolic compound found in a variety of plant materials, including fruits and vegetables like olives, dates, grapes, and spices. It is a potential antioxidant used in traditional Chinese medicine.
Within the broader framework of traditional medicine, syringic acid is an emerging nutraceutical and antioxidant used in modern Chinese medicine. The compound's presence across many plants with documented traditional medical use means that it has been consumed — though not specifically identified — for millennia as a constituent of foods and herbal preparations in Mediterranean, Asian, and Middle Eastern traditions.
Regarding early scientific interest, the focus of early 20th-century research at Columbia University was the use of syringic acid to produce 3,5-dimethoxyphenetidine, a compound under study as an antipyretic (fever reducer). This represents one of the earliest recorded pharmacological explorations of the compound.
It should be emphasized that claims of traditional use specific to syringic acid as a discrete compound — as opposed to the plant matrices in which it naturally occurs — are not well-documented in historical records. The modern research literature has investigated syringic acid largely through the lens of contemporary phytochemistry rather than specific ethnobotanical records attributing effects to this compound alone.
Syringic acid can modulate the dynamics of several biological targets such as proteins, transcriptional factors, growth factors, and signaling molecules involved in disease progression. The therapeutic activity of syringic acid is attributed to the presence of methoxy groups on the aromatic ring at positions 3 and 5. Syringic acid inhibits lipoprotein oxidation, scavenges free radicals, and reduces malondialdehyde production. The methoxy groups of syringic acid are responsible for scavenging free radicals.
Syringic acid exerts potent antioxidant and anti-inflammatory activities through multiple mechanisms. Specifically, it mitigates oxidative stress by scavenging free radicals, enhancing endogenous antioxidant defenses, and activating the KEAP1/NRF2 pathway.
The mechanistic picture is well-established: Nrf2 activation, NF-κB suppression, MAPK modulation, direct radical scavenging, and antihyperglycemic pathways collectively position syringic acid as a pleiotropic molecule with relevance to the oxidative stress, inflammation, and metabolic dysfunction that underlie aging-related diseases.
Syringic acid inhibits inflammation by downregulating key mediators, including NF-κB, TLR4, HMGB1, MyD88, and TRAF6. Crosstalk between NRF2, NF-κB, and PI3K/AKT pathways reveals syringic acid's involvement in cellular pathophysiological processes such as apoptosis, ferroptosis, and endoplasmic reticulum stress.
Different mechanisms such as increasing insulin level, restoring insulin sensitivity, and improving the consumption of glucose by peripheral tissues are responsible for syringic acid's antihyperglycemic effects. Syringic acid has the potential to modulate enzyme activity, protein dynamics, and diverse transcription factors involved in diabetes, inflammation, cancer, and angiogenesis.
In cancer cells, syringic acid promotes apoptosis through the mitochondria-dependent pathway, including the downregulation of BCL-2 and upregulation of P53, caspase-3, caspase-9, cytochrome C, BAX, and APAF1. Additionally, syringic acid promotes the phosphorylation of the upstream cAMP response element-binding protein (CREB) of Bcl-2, stabilizing the mitochondrial outer membrane and preventing cytochrome c release in non-cancer contexts.
Targeting aldose reductase (AR), syringic acid provides protection from galactose-induced damage by consistently maintaining lens transparency and delaying lens turbidity development. Inhibition of AR gene expression by syringic acid was confirmed by qRT-PCR. The IC₅₀ of syringic acid for inhibition of AR activity was 213.17 μg/mL. AR–syringic acid binding sites include Trp111, His110, Tyr48, Trp20, Trp79, Leu300, and Phe122. The main binding modes involved hydrophobic interactions and hydrogen bonding.
Syringic acid was reported to modulate genes that are associated with lipid metabolism, thereby preventing the formation of fat cells. It inhibits methyl cellosolve-induced hepatic and testicular inflammation by modulating the JAK-STAT and NF-κB signaling pathways.
Important caveat: The great majority of published evidence for syringic acid comes from in vitro (cell-based) and in vivo (animal) studies. The fundamental limitation is not the quality of the preclinical data — which is extensive and internally consistent — but the complete absence of human translation. No human pharmacokinetics, no established dose, no safety profile in humans, and no human efficacy data exist. All clinical claims must be interpreted in this context.
A 2025 systematic review published in Frontiers in Pharmacology (PMC12283738) systematically examined the antioxidant and anti-inflammatory evidence. A comprehensive literature review was conducted using PubMed and Web of Science (1965–2024) to investigate the antioxidant and anti-inflammatory mechanisms of syringic acid, with a focus on oxidative stress and inflammatory pathways. The search strategy incorporated keywords like "syringic acid," "oxidative stress," and "inflammation," identifying a total of 1,226 articles. Titles and abstracts were screened for relevance, and full texts were assessed according to PRISMA guidelines.
One PMC-indexed study evaluated syringic acid against dimethyl nitrosamine (DMN)-induced hepatotoxicity in rats. Following DMN administration, malondialdehyde (MDA), nitric oxide (NO), and reduced glutathione (GSH) as well as activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) were significantly elevated. Also significantly increased were levels of TNF-α, IL-1β, and NF-κB. Following treatment with syringic acid, the activities of ALT, AST, GPx, CAT, and SOD, as well as MDA, GSH, TNF-α, IL-1β, and NF-κB levels, were significantly reduced.
Evidence strength: Preclinical (animal and in vitro) only. No human randomized controlled trials exist. The antioxidant and anti-inflammatory effects are well-characterized mechanistically across multiple animal models, but clinical translation has not been demonstrated.
Among the more thoroughly studied areas, the antidiabetic effects of syringic acid have been examined across multiple animal models. A PMC-indexed study (PMC9573038) evaluated syringic acid in a streptozotocin-induced neonatal diabetic rat model. The treatment of syringic acid (25 mg/kg and 50 mg/kg, p.o.) was given from the 8th to 18th postnatal week. To assess the development of diabetic complications and the effect of therapy, biochemical indicators in serum and behavioural parameters were recorded at specific intervals. Syringic acid treatment reduced hyperglycaemia, polydipsia, polyphagia, polyuria, relative organ weight, cardiac hypertrophic indices, inflammatory markers, cell injury markers, glycated haemoglobin, histopathological score, and oxidative stress, and increased Na/K ATPase activity.
Syringic acid appears to have antioxidative, anti-inflammatory, antihyperglycaemic, and antihyperlipidaemic properties; it was found to protect against the neuronal, cardiac, hepatic, and renal damage caused by chronic hyperglycaemia in Wistar rats. As a result, syringic acid may be used to prevent type 2 diabetes mellitus-associated complications and/or organ damage.
A separate study published in PubMed (PMID 32072913) assessed syringic acid in the context of diabetic nephropathy: according to the results, syringic acid alters renal antioxidant defense mechanisms and could be considered as a novel approach by targeting mitochondria in renal diabetic complications.
Syringic acid has been reported for its antidiabetic, antiglycating, antisteatosis and anti-inflammatory, antioxidant and antihypertensive, and antibacterial and antimicrobial properties. It also ameliorates diabetic cataracts by suppressing the aldose reductase enzyme.
Evidence strength: Preclinical (rodent) only. Multiple animal studies consistently demonstrate antihyperglycaemic effects. No human clinical trials have been conducted.
A PMC-indexed study (PMC7787734) evaluated the neuroprotective properties of syringic acid in streptozotocin-induced diabetic rats. This study evaluated the possible neuroprotective effects of syringic acid, a natural polyphenolic derivative of benzoic acid, on oxidative damage and mitochondria in the brain, spinal cord, and sciatic nerve of streptozotocin-induced diabetic rats. Different groups of rats including normal control, diabetics, and diabetic groups treated with 25, 50, and 100 mg/kg of syringic acid, as well as a non-diabetic group treated with 100 mg/kg of syringic acid, were treated for 6 weeks. Learning and memory function, physical coordination, and acetylcholinesterase (AChE) and antioxidant indexes, as well as mRNA expression of mitochondrial biogenesis, were measured in the brain, spinal cord, and sciatic nerves. Diabetic rats treated with 100 mg/kg syringic acid exhibited significantly improved learning, memory, and movement deficiency (p < 0.05).
A further study (PMC11709963) evaluated the effects in a traumatic brain injury (TBI) rat model. Syringic acid treatment significantly restored antioxidant levels, attenuated increased AChE activity and TNF-α levels, and regained mitochondrial capacities. The results show that the therapeutic effect of syringic acid might involve the inhibition of inflammatory reactions against brain injury-induced cognitive dysfunction and neuroinflammation in rats. The current work demonstrates the neuroprotective effect of syringic acid in an experimental model of TBI. The study further suggests that the neuroprotective impacts of syringic acid may be related to its effects on TNF-α, IL-6 levels, oxidative stress pathways, and mitochondrial complex capabilities.
Additional neuroprotective data come from the Alzheimer's disease context: chitosan-coated nanocarrier-delivered syringic acid achieved a superior brain AUC₀–∞ with a 2.6-fold improved drug targeting efficiency in the brain of BALB/c mice. These improvements resulted in significant neuroprotective effects and decreased oxidative stress and inflammatory levels in Aβ₁–₄₂-induced mice. The study highlights safe and effective intranasal delivery of syringic acid via chitosan-coated nanocarrier as a promising Alzheimer's disease treatment strategy.
Evidence strength: Preclinical (animal) only. No human studies. Mechanistic data are well-defined in multiple rodent models of neurodegeneration and TBI.
The hepatoprotective potential of syringic acid has been assessed in several preclinical models. One study (PMID referenced as Itoh et al., 2010, Biol Pharm Bull) investigated the hepatoprotective effect against CCl₄-induced liver injury. A further study investigated syringic acid against acetaminophen-induced hepatic damage in albino rats (Ramachandran and Raja, 2010).
A study examining hepatic encephalopathy (ScienceDirect DOI: S0304394021007643) reported that syringic acid showed neuroprotective and hepatoprotective effects in hepatic encephalopathy. Ammonia level and hepatotoxicity biomarkers were decreased with syringic acid treatment. Syringic acid exhibited protective effects against hepatic inflammation, neuroinflammation, and behavioral disabilities. In this study, rats were treated with syringic acid (50 and 100 mg/kg, p.o.) for 14 days in treatment groups. In conclusion, syringic acid exerted hepatoprotective and neuroprotective effects against hepatic encephalopathy by mitigating hepatotoxicity biomarkers, exerting antioxidant and anti-inflammatory effects, in addition to suppressing hyperammonemia.
In DMN-induced hepatotoxicity, syringic acid's therapeutic effects were investigated in rats with dimethyl nitrosamine-induced hepatic injury. Following DMN administration, MDA, NO, and GSH as well as activities of ALT, AST, GPx, CAT, and SOD were significantly increased. Also increased were levels of TNF-α, IL-1β, and NF-κB. Following treatment with syringic acid, the activities of ALT, AST, GPx, CAT, and SOD, as well as MDA, GSH, TNF-α, IL-1β, and NF-κB levels, were significantly reduced.
Evidence strength: Preclinical (animal) only. Multiple liver-damage models consistently show hepatoprotective effects. No human clinical trials exist.
A PMC-indexed study (PMC8727109) examined syringic acid in streptozotocin-induced diabetic cardiomyopathy in rats. The study aimed to explore the syringic acid protective effect against diabetes-induced cardiac injury in experimental rats. Rats were divided into control and streptozotocin-induced diabetic rats, which were subdivided into diabetic controls and three test groups (syringic acid at 25, 50, and 100 mg/kg) and a non-diabetic group that received 100 mg/kg of syringic acid. All treatments were given syringic acid for 6 weeks. Syringic acid's effects on cardiac diagnostic markers, heart lipid peroxidation, protein carbonylation, antioxidant system, and changes of the heart mitochondrial mass and biogenesis were measured.
Syringic acid treatment showed protective effects on diabetic cardiomyopathy in rats by reducing lipid peroxidation and protein carbonylation. The possible mechanisms could be related to the antioxidant activity of this phenolic acid. Syringic acid might play a role of a protective factor in cardiac challenges in diabetes.
Syringic acid may have prevented the cytosolic activation of NF-κB, thereby preventing its ability to exert nuclear transcription activities. This anti-inflammatory effect of syringic acid, characterized by the significant decrease in mRNA expressions of NF-κB and TNF-α in isoproterenol-induced cardiotoxicity in rats, has also been reported.
Evidence strength: Preclinical (animal) only. No human clinical trials.
Multiple preclinical studies have examined syringic acid against different cancer cell lines. A study published in Chemico-Biological Interactions (2021) examined colorectal cancer: this study aimed to evaluate the in vitro effects of syringic acid on human colorectal cancer cells (SW-480) and the effect of orally administered syringic acid on in vivo models of colorectal cancer induced in rats by administration of 1,2-dimethylhydrazine (DMH). In vitro effects were assessed by performing cell proliferation assay, apoptosis assays, reactive oxygen species, antioxidant enzymes and DNA damage measurement, and evaluation of protein levels of proliferative genes and autophagy markers. The effect of orally administered syringic acid (50 mg/kg) on tumor growth and incidence was studied in four groups (n = 6) of animals injected with DMH and treated for 15 weeks. Syringic acid was reported to act as an anti-cancer agent by reducing cellular proliferation, inducing apoptosis, and altering autophagy through modulating oxidative stress and key proteins involved in cellular proliferation.
In gastric cancer cells (AGS cell line), a PMC study (PMC8712439) found that syringic acid-treated cells developed anti-cancer activities by losing mitochondrial membrane potential, cell viability, and enhancing intracellular ROS. Syringic acid selectively developed apoptosis in a dose-dependent manner via enhanced regulation of caspase-3, caspase-9, and Poly ADP-ribose Polymerase (PARP) while decreasing the expression levels of p53 and BCL-2. Syringic acid also lowered activities of SOD, CAT, and GSH-Px whereas TBARS increased. Syringic acid suppressed gastric cancer cell proliferation, inflammation, and induced apoptosis by upregulating mTOR via the AKT signaling pathway.
In oral squamous carcinoma cells, a PMC study (PMC7269318) found that syringic acid has long been used as traditional medicine and is known to have antioxidant, hepatoprotective, neuroprotective, and anticancer effects.
Evidence strength: Preclinical (in vitro and animal) only. All anticancer data derive from cell-line or animal experiments. No human clinical trials of syringic acid as an anticancer agent exist.
A study published in Biochemical and Biophysical Research Communications (2024) examined immunomodulatory effects in cyclophosphamide-induced immunosuppression. Syringic acid restores cyclophosphamide-induced immunosuppression in mice. It protects mice from cyclophosphamide-induced immunosuppression by lowering MDA levels and upregulating thymic IL-6, IL-7, IL-15, and FoxN1. Docking studies revealed syringic acid has protective effects via the IL-6, IL-7, IL-15, FoxN1, JAK3, STAT3, and STAT5 pathway.
Evidence strength: Preclinical (animal) only.
A PMC study (PMC3545393) examined the effects of syringic acid extracted from Herba dendrobii on diabetic cataract. Targeting aldose reductase, syringic acid provided protection from galactose-induced damage by consistently maintaining lens transparency and delaying lens turbidity development. Inhibition of AR gene expression by syringic acid was confirmed by qRT-PCR. Syringic acid acts to prevent diabetic cataract in rat lenses by inhibiting aldose reductase activity and gene expression, which has potential to be developed into a novel drug for the therapeutic management of diabetic cataract.
Evidence strength: Preclinical (in vitro + animal lens model) only.
A 2018 review by Srinivasulu Cheemanapalli and coauthors at Sri Krishnadevaraya University stated that syringic acid has antioxidant, antimicrobial, anti-inflammatory, and antiendotoxic properties and showed promise against diabetes, cancer, cardiovascular disease, cerebral ischemia, and neurological and liver damage. Syringic acid can be enzymatically degraded by some bacteria as a source of methane or methanol, and it is a component of phenolic extracts from various plants that have antioxidant and prooxidant activities. Antimicrobial studies of syringic acid remain predominantly at the in vitro level, with no clinical data available.
Syringic acid exhibits a wide range of pharmacological properties, including antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, neuroprotective, antimicrobial, antidiabetic, and antiendotoxic properties. The following body systems are associated with its preclinical activity:
No standardized therapeutic dose for humans has been established, as no human clinical trials of syringic acid supplementation have been completed. The following dosages appear in preclinical (animal) studies:
In terms of preparations and delivery systems, research has shown that syringic acid's bioavailability can be improved via intraperitoneal injection to bypass first-pass metabolism; however, this raises concerns about potential hepatic overexposure and associated toxicity. Optimizing drug delivery methods, such as nanoparticles, liposomes, or polymeric micelles, could improve its therapeutic potential, ensuring better tissue distribution and reducing the risk of toxicity.
Syringic acid is available in some research and supplement markets as a purified powder (for research use) or as a component of botanical extracts. Another key challenge is the variability in the pharmacokinetics of syringic acid derived from different sources. The differences in ADME (absorption, distribution, metabolism, and excretion) between plant-derived syringic acid and the purified metabolite need to be further studied to understand how these factors may influence clinical outcomes.
The rate of bioavailability of syringic acid can be determined by several factors, including its chemical structure and reactive groups, which may participate in enzymatic reactions in the liver and intestine. Detailed human pharmacokinetic data for syringic acid specifically are not available in the peer-reviewed literature.
The history of polyphenol research is replete with compounds that showed remarkable preclinical promise but failed to deliver proportional clinical benefits in humans (resveratrol being the most notable example), often due to poor bioavailability, rapid metabolism, or insufficient tissue concentrations. Researchers have flagged this as a key challenge for syringic acid as well.
Regarding novel delivery approaches, one 2024 study investigated chitosan-coated nanostructured lipid carriers (CH-SA-NLCs) for intranasal delivery of syringic acid: the in vitro sustained drug release closely correlated with in vivo pharmacokinetics, demonstrating a 1.7-fold increase in syringic acid's half-life compared to plain syringic acid. The CH-SA-NLCs achieved a superior AUC₀–∞ with a 2.6-fold improved drug targeting efficiency of syringic acid in the brain of BALB/c mice.
A formal subacute oral toxicity study published in Heliyon (2019; PMC6706588) used OECD guidelines to assess safety. According to OECD TG 407, rats were divided into 3 groups (n = 12). The dose of syringic acid was decided by limit test. Treatment and satellite groups received syringic acid at 1000 mg/kg/day (p.o.) for 14 days, whereas an equal volume of vehicle was given to control groups. In order to assess reversibility, satellite groups were kept for another 14 days post-treatment. The toxic signs, mortality, and body weight changes were recorded. On days 15 and 29, the rats were anesthetized to collect blood for estimation of hematological and biochemical parameters and then sacrificed to collect internal organs for weighing and histopathological studies.
During this subacute toxicity study, syringic acid was shown to be safe. Syringic acid has shown to be relatively non-toxic to animals, but toxic at high levels.
As no human clinical trial has evaluated supplemental syringic acid, the safety profile at pharmacological doses is entirely unknown. Animal toxicology studies have generally shown low toxicity at moderate doses, but the absence of human data means that adverse effects, drug interactions, and contraindications cannot be ruled out.
As a phenolic compound metabolized by Phase II conjugation enzymes (UGT, SULT), supplemental syringic acid could theoretically compete with medications that share these metabolic pathways. However, no drug interaction studies exist.
The long-term safety and efficacy of syringic acid, especially with regard to its potential hepatotoxicity after prolonged use, must be carefully evaluated in clinical trials. This concern is specifically raised by researchers noting that bypassing first-pass metabolism via non-oral routes may lead to hepatic overexposure.
Syringic acid is a component of phenolic extracts from various plants that have antioxidant and prooxidant activities. Like many polyphenols, its antioxidant properties may reverse to prooxidant effects at high concentrations — a phenomenon well-established in the broader phenolic acid literature, though not yet systematically characterized for syringic acid in humans.
Syringic acid's robust antioxidant and anti-inflammatory mechanisms underscore its promise as a therapeutic agent. Future research should address its pharmacokinetics, safety profile, and clinical potential. Syringic acid may be combined with currently available antihyperglycaemic medications to reduce their dosage, prevent undesirable side effects, and delay the onset of tolerance. However, additional research on the mechanisms of action via gene expression studies and target-specific studies is required.
Syringic acid is a well-characterized phenolic acid found broadly in the human diet, primarily in olives, dates, grapes, red wine, honey, and several spices. Its chemistry is fully elucidated, and its biosynthetic origins from the shikimic acid and lignin pathways in plants are understood. Across preclinical research, a consistent and mechanistically coherent picture emerges: syringic acid activates the Nrf2/KEAP1 antioxidant pathway, suppresses NF-κB and related inflammatory mediators, inhibits aldose reductase, and modulates apoptotic and cell-survival pathways. These mechanisms underlie demonstrated effects — in animal and cell-culture models — across diabetes, hepatic injury, neurodegeneration, cardiac damage, and cancer cell proliferation.
However, the evidence base is almost entirely preclinical. The fundamental limitation is not the quality of the preclinical data — which is extensive and internally consistent — but the complete absence of human translation. No human pharmacokinetics, no established dose, no safety profile in humans, and no human efficacy data exist. The compound therefore cannot be characterized as evidence-based for any therapeutic application in humans at the present time. Its dietary presence across numerous whole foods means that it is consumed regularly by most people in small quantities, but supplementation with isolated syringic acid at pharmacological doses remains without a demonstrated human evidence base.
Condiciones de salud que Ácido siríngico puede ayudar a apoyar.
Sistemas corporales que Ácido siríngico puede ayudar a apoyar.
Volver